Startup Alumis raises $259 million as it prepares for psoriasis trial

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Autonomic nervous system dysfunction more severe in patients with CHD and hypertension

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The aim of this observational study was to perform in-depth analysis of autonomic nervous

June 27, 2023

MEP Action Group Meets in Brussels to Discuss Regulatory Pathways for Psychedelics – Psychedelic Alpha

Next, Maryam Jabir shared her experience as a participant in a phase 2b study of psilocybin therapy for treatment-resistant depression. Having struggled with depression for

November 8, 2023

Pfizer shelves five mid- and early-stage programs

Pfizer is culling a handful of clinical programs, including trials in cancer and dermatology, it announced Tuesday. The cuts include two Phase II programs, one

November 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.